Sponsors (9)
The bill would make medication information more accessible and standardized on paper—potentially improving safety and saving substantial healthcare costs—while imposing compliance, printing, operational, and enforcement burdens that could raise costs, create waste, and slow digital innovation.
Patients (including seniors and those with chronic conditions) receive a standardized, plain‑language single‑page printed medication information (PMI) that improves understanding of dosing, warnings, and when to seek care, likely reducing medication errors and harm.
Many Americans and the health system could see large downstream cost savings (estimated $14.6–$26.2 billion annually) if standardized PMI reduces adverse drug events and improves adherence.
People without reliable internet or devices (including seniors, people with disabilities, and uninsured individuals) gain equitable access to medication safety information through a required paper option.
Drug manufacturers, pharmacies, and dispensers face new design, printing, and distribution costs that may be passed to consumers or increase drug and dispensing prices.
The paper‑requirement plus tight formatting and FDA approval timelines could slow adoption of electronic labeling innovations and delay urgent safety updates or product approvals.
A single‑page summary risks oversimplifying complex safety information and omitting details clinicians or some patients need for safe use.
Based on analysis of 3 sections of legislative text.
Introduced September 4, 2025 by Cliff Bentz · Last progress September 4, 2025
Requires the FDA to issue regulations within one year that mandate a standardized, single-page printed patient medication information (PMI) be included with prescription drugs. Manufacturers must develop and submit the PMI for FDA approval as part of drug applications; failure to provide the required printed PMI will be a misbranding violation. The law specifies authorship, content, format, printing, distribution, and update requirements for PMI (plain language, graphics when appropriate, minimum font and color standards, one printed PMI per prescription, manufacturer contact info, adverse reaction and use guidance, and links to FDA reporting). It also directs the FDA to base specifications on patient research and to ensure timely review and consistency across related products.